Atlas One · Host Biology · Scale 07 — System

Chronic Myelomonocytic Leukemia

Chronic myelomonocytic leukemia (CMML) is an MDS/MPN overlap with persistent monocytosis; TET2 (~60%) and SRSF2 (~45%) are the dominant mutations; PDGFRB rearrangements → imatinib-responsive CMML-like disease. Azacitidine is standard; allo-SCT is the only cure; OS ~2 years.

Also known as: CMML, chronic myelomonocytic leukemia, CMML-0, CMML-1, CMML-2, myelodysplastic/myeloproliferative neoplasm, MDS/MPN overlap, proliferative CMML, myelodysplastic CMML

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
cmml

Chronic Myelomonocytic Leukemia

Chronic myelomonocytic leukemia (CMML) is an MDS/MPN overlap with persistent monocytosis; TET2 (~60%) and SRSF2 (~45%) are the dominant mutations; PDGFRB rearrangements → imatinib-responsive CMML-like disease. Azacitidine is standard; allo-SCT is the only cure; OS ~2 years.

Entry Metadata

FieldValue
IDcmml
NameChronic Myelomonocytic Leukemia
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toSrsf2 connects-toDnmt3A connects-toKras connects-toNf Kb connects-toTet2 connects-toJak2 connects-toMacrophage connects-toMyeloproliferative Neoplasms connects-toMds connects-toBone Marrow

Sources